Radiolabeled Receptor Modulators

MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with K i of 0.14 μM for [ 3 H]glycine binding in vitro and in vivo.In VitroMDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to

MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with K i of 0.14 μM for [ 3 H]glycine binding in vitro and in vivo.In VitroMDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to

MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with K i of 0.14 μM for [ 3 H]glycine binding in vitro and in vivo.In VitroMDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to

ML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).

ML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).

ML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).

ML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).

ML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).

ML-204 selectively blocks transient receptor potential canonical 4 (TRPC4) channels (IC₅₀s = 0.96 and 2.

ML-204 selectively blocks transient receptor potential canonical 4 (TRPC4) channels (IC₅₀s = 0.96 and 2.

ML-204 selectively blocks transient receptor potential canonical 4 (TRPC4) channels (IC₅₀s = 0.96 and 2.

InformationML397 (VU0155094) is a positive allosteric modulator (PAM) with differential activity at the various group III mGlus.